Novetide

Company Overview

Snapshot

Founded in January 1999, Novetide operated with 11–50 employees, specializing in peptide development and manufacturing.

Business overview

Novetide is a Health Tech & Life Sciences company focused on the development and manufacture of peptide products. Leveraging proprietary technologies, the company specializes in sequence assembly, downstream processing, characterization, and documentation of peptide drug substances. Novetide serves multinational pharmaceutical companies, startups, and researchers globally with FDA-approved production sites capable of manufacturing peptides from grams to tons. Its core products include Eptifibatide, Desmopressin acetate, Octreotide acetate, Teriparatide acetate, Atosiban acetate, and Bivalirudin.

Strategic signal

This event signals a consolidation within the peptide manufacturing sector, indicating that its technology and assets have likely been integrated into the acquiring entity's portfolio, thereby impacting the competitive landscape for peptide supply.

Company Intelligence Q&A

When was Novetide founded?

Novetide was founded in January 1999.

What is Novetide's primary business?

Novetide specializes in the development and manufacture of commercially available peptide products, with a pipeline of products under development.

What kind of products does Novetide manufacture?

Novetide manufactures peptide products such as Eptifibatide, Desmopressin acetate, Octreotide acetate, Teriparatide acetate, Atosiban acetate, and Bivalirudin.

Which company held a significant stake in Novetide?

Teva Pharmaceuticals has held 50% of Novetide since 2000.